Published in Ann Neurol on September 01, 2003
Stem cells in human neurodegenerative disorders--time for clinical translation? J Clin Invest (2010) 3.62
Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain (2005) 3.61
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med (2008) 2.80
Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest (2005) 2.25
Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke (2008) 2.18
Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet (2014) 2.12
Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques. J Clin Invest (2012) 2.11
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10
Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc Natl Acad Sci U S A (2007) 2.03
Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol (2014) 2.00
Cell therapy in Parkinson's disease. NeuroRx (2004) 1.93
Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease. Neurology (2009) 1.59
Use of placebo controls in the evaluation of surgery: systematic review. BMJ (2014) 1.57
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med (2011) 1.52
Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. Eur J Neurosci (2010) 1.51
Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports (2013) 1.48
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
Specification of neuronal and glial subtypes from human pluripotent stem cells. Cell Mol Life Sci (2011) 1.40
Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord (2006) 1.39
Report: Stem cell applications in neurological practice, an expert group consensus appraisal. Ann Indian Acad Neurol (2016) 1.37
Cell therapeutics in Parkinson's disease. Neurotherapeutics (2011) 1.32
Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest (2008) 1.29
Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med (2006) 1.29
Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model. J Cell Mol Med (2011) 1.27
Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain. Cell Rep (2013) 1.26
Immune problems in central nervous system cell therapy. NeuroRx (2004) 1.21
Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector. PLoS One (2011) 1.21
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology (2011) 1.21
Targeting neural precursors in the adult brain rescues injured dopamine neurons. Proc Natl Acad Sci U S A (2009) 1.21
Placebo and the new physiology of the doctor-patient relationship. Physiol Rev (2013) 1.20
Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med (2009) 1.20
Ethical issues in stem cell research. Endocr Rev (2009) 1.20
Nonviral direct conversion of primary mouse embryonic fibroblasts to neuronal cells. Mol Ther Nucleic Acids (2012) 1.20
Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther (2013) 1.18
Neuroimaging and therapeutics in movement disorders. NeuroRx (2005) 1.17
Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol (2005) 1.17
Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells (2006) 1.16
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 1.12
Neurogenesis and brain injury: managing a renewable resource for repair. J Clin Invest (2003) 1.08
Clinical application of stem cell therapy in Parkinson's disease. BMC Med (2012) 1.07
Stem cells in clinical practice: applications and warnings. J Exp Clin Cancer Res (2011) 1.06
Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients. J Neurol (2009) 1.05
Human embryonic stem cells for brain repair? Philos Trans R Soc Lond B Biol Sci (2008) 1.04
Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord (2010) 1.02
Engraftment of human nasal olfactory stem cells restores neuroplasticity in mice with hippocampal lesions. J Clin Invest (2011) 1.01
Neurodegeneration and cell replacement. Philos Trans R Soc Lond B Biol Sci (2008) 1.01
Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease. J Med Ethics (2007) 1.01
Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med (2010) 1.01
Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease. J Neurol (2011) 1.00
Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson's disease and multiple system atrophy. J Clin Neurol (2009) 0.99
Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS One (2007) 0.99
Neural tissue engineering using embryonic and induced pluripotent stem cells. Stem Cell Res Ther (2011) 0.99
Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci (2008) 0.98
Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol Dis (2007) 0.98
Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol (2015) 0.97
Neural stem/progenitor cells as a promising candidate for regenerative therapy of the central nervous system. Front Cell Neurosci (2012) 0.96
Spheramine for treatment of Parkinson's disease. Neurotherapeutics (2008) 0.96
Retinal pigment epithelial cells secrete neurotrophic factors and synthesize dopamine: possible contribution to therapeutic effects of RPE cell transplantation in Parkinson's disease. J Transl Med (2009) 0.96
Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol (2004) 0.95
Neuroimaging in Parkinson's disease. Neurotherapeutics (2011) 0.95
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors. Neurobiol Dis (2008) 0.95
To what extent are surgery and invasive procedures effective beyond a placebo response? A systematic review with meta-analysis of randomised, sham controlled trials. BMJ Open (2015) 0.94
Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain (2008) 0.94
Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. Curr Neuropharmacol (2007) 0.94
Moving stem cells to the clinic: potential and limitations for brain repair. Neuron (2015) 0.94
Transplantation of GABA-producing cells for seizure control in models of temporal lobe epilepsy. Neurotherapeutics (2009) 0.93
Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells. J Cell Mol Med (2009) 0.93
What happened to posteroventral pallidotomy for Parkinson's disease and dystonia? Neurotherapeutics (2008) 0.92
Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics (2014) 0.92
Future of cell and gene therapies for Parkinson's disease. Ann Neurol (2008) 0.92
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson's disease: a pilot clinical study. Stem Cells Int (2012) 0.91
Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? BMC Med (2010) 0.91
Long-term MRI cell tracking after intraventricular delivery in a patient with global cerebral ischemia and prospects for magnetic navigation of stem cells within the CSF. PLoS One (2014) 0.91
The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue? Front Pharmacol (2014) 0.90
Devices for cell transplantation into the central nervous system: Design considerations and emerging technologies. Surg Neurol Int (2013) 0.89
Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinsons Dis (2012) 0.89
Conditions for tumor-free and dopamine neuron-enriched grafts after transplanting human ES cell-derived neural precursor cells. Mol Ther (2009) 0.89
Experimental therapies for Parkinson's disease: Why fake it? Nature (2011) 0.88
The potential for cell-based therapy in perinatal brain injuries. Transl Stroke Res (2013) 0.88
Neuroimaging in Parkinson's disease. NeuroRx (2004) 0.88
"NeuroStem Chip": a novel highly specialized tool to study neural differentiation pathways in human stem cells. BMC Genomics (2007) 0.88
Intracerebral transplantation of differentiated human embryonic stem cells to hemiparkinsonian monkeys. Cell Transplant (2013) 0.88
Prion-like propagation of protein aggregation and related therapeutic strategies. Neurotherapeutics (2013) 0.88
Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Exp Neurol (2007) 0.88
AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons. Exp Neurol (2008) 0.88
Sham surgery trial controls: perspectives of patients and their relatives. J Empir Res Hum Res Ethics (2012) 0.87
Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. J Comp Neurol (2009) 0.87
Hydrogel formulation determines cell fate of fetal and adult neural progenitor cells. Stem Cell Res (2013) 0.87
The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. J Cereb Blood Flow Metab (2008) 0.86
Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? J Comp Neurol (2014) 0.86
The effect of striatal dopaminergic grafts on the neuronal activity in the substantia nigra pars reticulata and subthalamic nucleus in hemiparkinsonian rats. Brain (2011) 0.86
Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep (2004) 0.85
Positron emission tomography neuroimaging in Parkinson's disease. Am J Transl Res (2011) 0.85
Cell-based therapies for Parkinson's disease: past, present, and future. Antioxid Redox Signal (2009) 0.85
The Interplay between Alpha-Synuclein Clearance and Spreading. Biomolecules (2015) 0.84
The promise of stem cells in Parkinson disease. J Clin Invest (2005) 0.84
Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother (2011) 0.84
Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson's disease, the aphakia (ak) mouse. Cell Transplant (2012) 0.84
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol (2004) 6.14
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol (2010) 4.48
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache (2010) 4.37
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 3.46
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Exposure to indoor pesticides during pregnancy in a multiethnic, urban cohort. Environ Health Perspect (2003) 3.25
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol (2005) 2.68
Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol (2007) 2.62
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol (2012) 2.29
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis (2006) 2.23
Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol (2006) 2.17
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
PET performance measurements using the NEMA NU 2-2001 standard. J Nucl Med (2002) 2.06
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Pilot study of urinary biomarkers of phytoestrogens, phthalates, and phenols in girls. Environ Health Perspect (2007) 2.04
Childhood obesity and neighborhood food-store availability in an inner-city community. Acad Pediatr (2009) 2.01
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord (2008) 1.98
Levodopa-induced dyskinesias. Mov Disord (2007) 1.94
Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol (2008) 1.93
The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci (2003) 1.92
The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology (2008) 1.92
Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol (2007) 1.91
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord (2011) 1.87
Dorsal striatal D2-like receptor availability covaries with sensitivity to positive reinforcement during discrimination learning. J Neurosci (2011) 1.82
Race and food store availability in an inner-city neighbourhood. Public Health Nutr (2007) 1.81
Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women. J Oncol (2009) 1.81
Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry (2006) 1.79
Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord (2012) 1.76
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol (2003) 1.74
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain (2003) 1.70
Resolution modeling in PET imaging: theory, practice, benefits, and pitfalls. Med Phys (2013) 1.69
Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry (2003) 1.69
Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord (2013) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol (2003) 1.64
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. Prog Neurobiol (2011) 1.61
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics (2013) 1.58
Irrational choice under uncertainty correlates with lower striatal D(2/3) receptor binding in rats. J Neurosci (2012) 1.57
Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry (2010) 1.57
Neuropathic features in fragile X premutation carriers. Am J Med Genet A (2007) 1.56
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol (2002) 1.55
Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci (2005) 1.55
Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol (2014) 1.55
Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol (2004) 1.55
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Neurosurgery (2002) 1.54
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Part 1: the history of 19th century neurology and the American Neurological Association. Ann Neurol (2003) 1.54
Statistical dynamic image reconstruction in state-of-the-art high-resolution PET. Phys Med Biol (2005) 1.50
Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology (2013) 1.50
Prevalence of childhood asthma in urban communities: the impact of ethnicity and income. Ann Epidemiol (2005) 1.49
Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol (2003) 1.49
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol (2005) 1.48
Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol (2005) 1.48
Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex (2004) 1.48
Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br J Psychiatry (2010) 1.45
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci (2011) 1.45
An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol (2002) 1.44
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord (2013) 1.44
Clustering of Parkinson disease: shared cause or coincidence? Arch Neurol (2004) 1.42
Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord (2005) 1.41
Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol (2004) 1.41